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Mother-to-Child Transmission of Human Immunodeficiency 
Virus Type 1 (HIV-1) and Its Determinants: A Cohort Study in 
Kigali, Rwanda 
Philippe Lepage,' Philippe Van de Perrer2 Philippe M~ellati,~ Deo-Gratias Hitimana,' 
Arlette Simonon,2 Christiaan Van Goethem,' Barbara Mukamabano,' Etienne Karita,2 
Anne-Maria Stevens,' Guy mat hie^,^ Roger Salam~n,~ and François Dabis3 
The authors report the results of the first 2 years of follow-upõf a prospective cohort 
study on the mother-to-child transmission of human immunodeficiency virus type 1 
(HIV-1) and its determinants which started in November 1988 in Kigali, Rwanda. The 
study sample consists of 218 newborns of 215 HIV-1 seropositive women matched to 
218 newborns of 216 HIWI seronegative women of the same age and parity. They 
were followed every 2 weeks during the first 2 years of follow-up. HIV-1 antibodies 
were detected by enzyme-linked immunoadsorbent assay and Western blot at 3-month 
intervals. Two methods of calculating the mother-to-child transmission rate were used: 
method 1 combines the information provided by the persistence of HIV-1 antibodies at 
15 months of age in children born to HIV seropositive mothers and the excess mortality 
in this group compared with the cohort of children born to HIV seronegative mothers; 
method 2 is a case-by-case evaluation of all the children born to HIV seropositive 
mothers. A logistic regression model was used to study the determinants of transmis- 
sion. The probability of survival at 24 months of age was 81 % (95% confidence interval 
(CI) 75-86) in children born to seropositive mothers, compared with 95% (95% CI 92- 
98) in children born to seronegative mothers (p c 0.001). The mother-to-child transmis- 
sion rate calculated with method 1 was 25.7% f95% CI 18.8-32.5). With method 2. the 
medium estimate was 24.7%. In the multivariate analysis, a CD4jCD8 ratio c0.5 was 
dhe only maternal factor statistically associated with an increased risk of mother-to-child $? 7 
(ransmission of HIV-1 (odds ratio = 2.9,95% CI 1.2-7.2). The authors' findings present u ) %  
bvidence for a hinher mother-to-child transmission rate of HIV-1 in children born in ! 5 w  
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(1). Most children acquire HIV infection 
from their mothers in utero, during delivery, 
or in the post-partum period through breast 
feeding (2-4). The rate of HIV-1 transmis- 
sion from infected mothers to their offspring 
varies in published series from 13 percent to 
45 percent, with a tendency toward higher 
rates in African studies (5- 15). The reason 
for this variability between studies remains 
unclear. However, there is no commonly 
accepted method of calculation of the 
mother-to-child rate of HIV- 1 transmission. 
Furthermore, until now few studies have 
addressed the issue of the determinants of 
perinatal transmission (5, 1 1, 16). 
In November 1988, a prospective cohort 
study on the perinatal transmission of HIV- 
1 was undertaken in Kigali, the capital of 
Rwanda, Central Africa. In this city, the 
prevalence of HIV- 1 infection among young 
adults of both sexes averages 30 percent (1 7). 
In this article, we report the key results of 
the first 2 years of follow-up of this cohort. 
Estimates of the rate of transmission of HIV- 
1 from infected mothers to their offspring 
have been made using methods recently pro- 
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posed by an International Working Group 
(18). Finally, we tried to shed light on the 
factors that might contribute to the observed 
level of transmission in this population. 
1 
; 
MATERIALS AND METHODS 
Study population 
A prospective cohort study has been on- 
going in Kigali, Rwanda, since November 
1988. Details of the enrollment procedures 
have been published elsewhere (1 9). Briefly, 
HIV testing was offered between November 
1988 and June 1989 to all women delivering 
in the Maternity Ward of the Centre Hos- 
pitalier de Kigali and fulfilling the following 
inclusion criteria: delivering a livebirth, liv- 
ing permanently within the city limits, and 
giving informed consent to participate. The 
study sample consists of 218 newborns of 
2 15 HIV- 1 seropositive women matched to 
218 newborns of 216 HIV-1 seronegative 
women ofthe same age (22 years) and parity 
(rtl pregnancy), who delivered during the 
same period. 
The children and their mothers were fol- 
lowed every 2 weeks during the first 2 years 
of follow-up. They were either visited at 
home by a social worker or attended the 
outpatient clinic organized within the 
Mother and Child Health Clinic of the 
Centre Hospitalier de Kigali. A systematic 
clinical examination was performed by one 
of the pediatricians participating in the proj- 
ect every 3 months, and whenever necessary 
for medical care. All the children were im- 
munized during the first 15 months of life 
following the recommendations of the 
Rwandese Expanded Programme of Immu- 
nization, with one exception: a high dose 
Edmonston-Zagreb measles vaccine was 
given at 6 months of age in the place of the 
Schwarz vaccine at 9 months (20, 21). 
Serologic methads 
At delivery and at 3-month intervals 
thereafter, the child and mother’s sera were 
tested for HIV- 1 antibodies by a commercial 
enzyme-linked immunoadsorbent assay 
(ELISA) (EIA, Vironostika, Organon Tek- 
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nika, Boxtel, the Netherlands). Samples that 
tested positive were further confirmed by a 
commercial Western blot technique (Du 
Pont, Wilmington, Delaware) using the Cen- 
ters for Disease Control criteria of interpre- 
tation (22). 
Mother's sera collected at delivery were 
tested for Chlamydiae antibodies by a 
commercial ELISA (Immun0 Comb bi- 
spot, Produit Biotechnologie Strasbourg, 
Hillkirch, France) and for syphilis antibodies 
by non-treponemal test (VDRL, latex, Well- 
come, Dartford, England) and treponemal 
test (TPHA, Wellcome). A recent syphilis 
infection was defined by dual positive 
VDRL and TPHA tests. 
A blood sample was obtained from the 
mother 2 weeks after delivery. Mononuclear 
cell subpopulations were quantitated using 
an indirect immunofluorescence technique 
and monoclonal antibodies: OKT4 for 
helper-inducer T-cells (CD4) and OKT8 for 
suppressor-cytotoxic T-cells (CD8) (Ortho 
Diagnostic System, Raritan, New Jersey). A 
reversed CD4/CD8 ratio was considered as 
the criterion for impaired cellular immunity 
(23). 
Case definitions 
Criteria used to define children born to 
seropositive mothers as infected with HIV- 
1, uninfected, or with an indeterminate sta- 
tus are presented in table 1. The use of this 
classification was restricted to children who 
had or could have reached the cut-off age of 
15 months at the time of analysis. It takes 
into account the HIV- 1 antibody serostatus 
at 15 months of age and when the last con- 
tact occurred before 15 months of age, the 
presence or absence of signs and symptoms 
(1 8). 
Death was defined as HIV-related either 
in a child with AIDS or in a child with at 
least one HIV-related sign/symptom when 
last seen and dying from severe infection or 
persistent diarrhea beyond the first 4 weeks 
of life. The following signs and symptoms 
were regarded as HIV-related: persistent 
diarrhea (214 days), failure to thrive ( 4 0  
percent weight for age), persistent general- 
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ized lymphadenopathy, oral candidiasis (be- 
yond the neonatal period), severe or recur- 
rent pneumonia, chronic parotitis, and her- 
pes zoster infection. 
Children with at least two major and two 
minor signs of the World Health Organiza- 
tion (WHO) clinical case definition of pedi- 
atric acquired immunodeficiency syndrome 
(AIDS) (24) were considered to have AIDS. 
However, one modification was made to the 
WHO definition: if present, severe pulmo- 
nary infection (respiratory rate 250 in chil- 
dren 1-1 l months old or 240 in children 
12-23 months old) or recurrent pulmonary 
infection (22 episodes during follow-up) was 
considered as a major sign in the place of 
chronic cough as a minor sign (25) . 
Statistical methods 
Probabilities of survival were computed 
according to the Kaplan-Meier product limit 
method. The 95 percent confidence intervals 
were calculated using Rothman's formula 
Two methods were used for calculating 
the mother-to-child transmission rate of 
Method 1. A combination of the infor- 
mation provided by the persistence of HIV- 
1 antibodies at 15 months of age in children 
born to HIV-1 seropositive mothers and by 
the excess mortality in this group compared 
with the reference cohort constituted of chil- 
dren born to HIV-l seronegative mothers 
(Method 1). Method 1 was originally pro- 
posed by Halsey et al. (14) in Haiti and was 
subsequently revised (1 8) to obtain the fol- 
lowing equation: 
(26). 
HIV-1 (TR): 
where ml = probability of dying before 15 
months for children born to an HIV-1 sero- 
positive mother; mo = probability of dying 
before 15 months for children born to an 
HIV-1 seronegative mother; and p = pro- 
portion of surviving children born to HIV- l 
seropositive mothers who are HIV-1 anti- 
body positive at 15 months. 
Standard deviations and 95 percent con- 
firlpnrp interxralc x w n r e  rnm-ir tnA fn- +h- -- 
timate of TR obtained with this first method 
(1 8). 
Method 2. A case-by-case evaluation of all 
the children born to HIV-1 seropositive 
mothers according to the classification pre- 
sented in table 1 yields a direct estimate of 
TR with 95 percent confidence interval. To 
refine this method, three estimates of TR 
can be made when considering the three 
categories of children: infected (ri+), unin- 
fected (n-), and with indeterminate HIV- 1 
infection status (n?). Let Ndenote the overall 
number of children born to HIV-1 seropos- 
itive mothers: 
N = (n+) + (n-) + (n?). 
A lower estimate of TR is: 
An medium estimate is: 
TR, ='n+/[(n+) + (n-)]. 
An upper estimate is: 
TR,, = [(fi+) + (n?)]/N. 
After univariate analysis, a logistic regres- 
sion model was used to assess the association 
between pediatric HIV- 1 infection (defined 
as above in method 2) and explanatory co- 
variates grouped in four categories: history 
of adverse pregnancy outcome (defined by 
the proportion of stillbirths and abortions 
out of the total number of pregnancies), 
maternal clinical and immunologic status, 
circumstances of delivery of the mothers and 
sexually transmitted diseases diagnosed at 
the time of delivery. The factors found to 
have a p value c 0.30 in the univariate 
analysis were included in the model. This 
analysis was performed with the EGRET 
software (Statistical Epidemiology Research 
Corporation, Seattle, Washington). 
RESULTS 
Survival experience of the cohort and 
analysis of the causes of death 
Out of 2 18 newborns of HIV-1 seroposi- 
mnthnto A n  Il Q 3 -m.-,-,--+\ d:-d --d ?I 
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(9.6 percent) were lost to follow-up during 
the first 24 months of life. Altogether, this 
cohort of children accounts for 4,392 
months of follow-up, i.e., 366 child-years. 
Among the 21 children lost to follow-up, 
only nine (4.1 percent) were lost before they 
could be classified as HIV-1 infected or un- 
infected (table 2). 
Out of 2 18 newborns of HIV- 1 seronega- 
tive mothers, 10 (4.6 percent) died (includ- 
ing one who seroconverted postnatally to 
HIV-I (4)) and 15 (6.9 percent) were lost to 
follow-up during the first 24 months of life. 
Altogether, this cohort of children born to 
HIV- 1 seronegative mothers accounts for 
4,924 months of follow-up, i.e., 410 child- 
years (table 2). 
All the children were breast-fed from 
birth. The proportion of children who were 
still breast-fed remained high at 12 and 24 
months, 88 percent and 68 percent respec- 
tively, without any difference between the 
two cohorts. 
Figure 1 shows the cumulative probability 
of survival of children born to HIV-1 sero- 
positive and HIV- 1 seronegative mothers 
TABLE 2. Summary of the first 2 years of follow-up of the cohort of children born to human 
immunodeficiency virus type 1 (HIV-1) positive and negative mothers, Kigali, Rwanda, 1988-1991 
Children born to 
HIV-1 positive mothers HIV-1 negative mothers Time after birth 
to Child-months No. of Loss to No. of deaths follow-up Child"nths deaths follow-up 
~ 
0-90 days* 
4-6 months 
7-9 months 
10-12 months 
13-1 5 months 
16-1 8 months 
19-21 months 
22-24 months 
Total 
~~ 
11 
4 
4 
8 
4 
5 
1 
3 
40 
O 
4 
5 
3 
1 
O 
5 
3 
21 
629 
61 O 
583 
547 
528 
51 2 
500 
483 
4,392 
4 
2 
'1 
2 
O 
O 
O 
1 
10 
O 
1 
1 
2 
4 
1 
5 
1 
15 
642 
639 
629 
625 
61 O 
601 
595 
583 
4,924 
* 1-3 months. 
Probabl l l ty  of surv iva l  
("/.I 
t t 
I 1- 
f t r- 80 - 
60 7 0 1  
FIGURE 1. Cumulative probability of survival 24 months after birth in children born to human immunodeficiency 
virus type 1 (HIV-1) seropositive and seronegative mothers, Kigali, Rwanda, 1988-1 991. The upper curve shows 
the probability of survival of children born to HIV-1 seronegative mothers. The lower curve shows the probability of 
survival of children born to HIV-1 seropositive mothers. 
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during the first 2 years of follow-up. A sta- 
tistically significant difference in survival 
rate was found between the two groups, with 
a probability of survival of 81 percent (95 
percent CI 75-86) at 24 months of age in 
children born to HIV- 1 seropositive moth- 
ers, in contrast to a probability of survival 
of 95 percent (95 percent CI 92-98) in chil- 
dren born to HIV- l seronegative mothers ( p  
< 0.00 1, log-rank test). 
Table 3 summarizes the causes of deaths 
among children born to HIV- 1 seropositive 
and HIV- 1 seronegative mothers, during the 
first 24 months of follow-up. In children 
born to HIV- 1 seropositive mothers, diar- 
rheal diseases and pulmonary infections ac- 
counted for 53 percent of the deaths occur- 
ring in the first 2 years of life (table 3).  Four 
of the 10 deaths among children born to 
HIV- 1 seronegative mothers occurred in the 
early neonatal period (first week of life). 
Among the 40 children born to HIV-1 sero- 
positive mothers who died, 23 (57.5 percent) 
were classified as HIV-1-infected, 16 (40 
percent) had an indeterminate status for 
HIV-1 infection and one (2.5 percent) was 
considered as uninfected. This latter child 
died of fever of unknown origin. 
Loss of maternal HIV-1 antibodies 
Figure 2 shows the follow-up data on the 
rate of loss of maternal HIV-1 antibodies 
according to the age of the children. At birth, 
100 percent of children had antibodies to 
HIV- 1. At 12 months of age, 20 percent of 
the surviving children had HIY- 1 antibodies, 
while at 15 months of age, 17 percent had 
HIV-1 antibodies. No loss of HIV-1 anti- 
bodies occurred after 15 months of age. The 
mean duration of HIV-1 antibody persis- 
tence was 250 days (8.2 months) (median, 
226 days; range, 66-490 days). 
Mother-to child transmission rate of 
HIV-1 
The cumulative probability of death at 15 
months of age was 14.6 percent in the cohort 
of children born to HIV-1 seropositive 
mothers and 4.1 percent in the cohort of 
children born to HIV- 1 seronegative moth- 
ers, giving a '10.5 percent excess mortality in 
the HIV-1-exposed group. When this excess 
mortality figure is combined to the 17 per- 
cent Western blot positivity observed at 15 
months of age (figure 2), the estimated rate 
of mother-to-child transmission, calculated 
TABLE 3. Causes of death among the children of the cohort of mother-to-child transmission of human 
immunodeficiency virus type 1 (HIV-1), Kigali, Rwanda, 1988-1991 
Children born to HIV-1 seropositive mothers 
Children born to 
Indeterminate HIV-1 seronegative 
HIV infection HIV-uninfected HIV-infected* mothers 
status 
Diarrhea: 
Acute 4 1 
Persistent* 7 1 
Total 4 8 1 
Pneumonia 3 6 2 
Congenital malformation 4 
Prematurity/dysmaturity 3 
Fever of unknown origin 
Sepsis/meningitis 
Severe malaria 
Other cause 1 
Unknown 1 
1 3 
2 
2 2 
2 It 
1 1 
1 1 
Total 16 1 23 10 
* See definition in Materials and Methods section and table 1. 
t Postnatal mother-to-child seroconversion (see reference 4). 
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FIGURE 2. Loss of maternal human immunodeficiency virus antibodies according to age in children born to HIV-1 
seropositive mothers, Kigali, Rwanda, 1988-1 991. Percent positive by Western blot antibody test. NA, no specimen 
available. 
with mdhod 1, was 25.7 percent (95 percent 
With method 2, 46 (21.1 percent) of the 
218 children born to HIV-I seropositive 
mothers, were classified as HIV- 1-infected 
and 140 (64.2 percent) as uninfected. For 32 
children ( 14.7 percent), the HIV- 1 infection 
status remained indeterminate. This 
subgroup is made of 14 children who died 
before 15 months with indeterminate rela- 
tion to HIV-1 infection, two children who 
died of probable not HIV- 1-related cause 
while seropositive before 15 months, nine 
children who were lost to follow-up while 
seropositive before 15 months, and seven 
children who were known to be alive at 24 
months of age but could neither be exam- 
ined clinically nor tested for the presence of 
HIV- 1 antibodies. Thus, three estimates of 
TR can be made with their 95 percent CI: 
TRI = 2 1.1 percent (1 5.7-26.5); TR, = 24.7 
percent (18.5-30.9); TR, = 35.8 percent 
(29.4-42.1). 
CI 18.8-32.5). 
Determinants of mother-to-child 
transmission of HIV-1 
Among the 218 children born to HIV-1- 
positive mothers, the HIV- 1 infection status 
was ascertained for 186 of them (46 infected 
and 140 uninfected). All the items selected 
for the multivariate analysis were completed 
for 135 children (30 children infected and 
105 children uninfected). There was no 
significant difference on the inclusion and 
follow-up characteristics between these 1 35 
children and the 5 1 others. ' 
In the univariate analysis, the clinical sta- 
tus of the mother at delivery and during the 
15 first months of follow-up (asymptomatic, 
symptomatic with regard to HIV-1 infec- 
tion, or clinical AIDS) and the mode of 
delivery were not related to HIV- 1 infection 
in the child ( p  value = 0.94 and 0.64, re- 
spectively). 
We included in the logistic regression 
model the following variables: recent syphi- 
lis ( p  = 0.10 in univariate analysis), Chla- 
mydiae infection ( p  = 0.30), advanced ma- 
ternal age greater than 25 years ( p  = 0.24), 
adverse pregnancy outcome ( p  = 0.035), 
and CD4/CD8 ratio ~ 0 . 5  ( p  = 0.01). 
In the multivariate analysis, only a CD4/ 
CD8 ratio C0.5 remained statistically asso- 
ciated with an increased risk of mother-to- 
child transmission of HIV-1 (table 4). Thus, 
HIV- 1 seropositive mothers with severe im- 
munosuppression were 2.9 times more likely 
596 Lepage et al. 
TABLE 4. Maternal variables studied as possible determinants of mother-to-child transmission of human 
immunodeficiency virus type 1 (HIV-1) in 135 children born to seropositive mothers, Kigali, Rwanda, 1988- 
1991 
_ _ ~  
Frequency (%) Frequency 
in HIV-1- pó) in 
Variable infected* un infect ed * 
children children 
P 
95% 
confidence 
interval 
Odds 
ratiot 
(n = 30) (n = 105) 
CD4/CD8 ratio ~ 0 . 5  13 (43) 21 (20) 2.88 1.15-7.22 0.024 
abortion or stillbirth 12 (40) 22 (21) 2.1 2 0.85-5.28 0.108 
Age >25 years 15 (50) 40 (38) 1.80 0.74-4.35 0.195 
fection 4 (13) 5 (5) 2.55 0.56-1 1.6 0.225 
Chlamydiae infection 7 (23) 16 (15) 1.18 0.39-3.57 0.775 
History of at least one 
Recent* syphilis in- 
*See definition in Materials and Methods section. 
t Computed by logistic regression model. 
to transmit HIV-1 infection to their off- 
spring than HIV- 1-infected women without 
severe immunologic impairment. Although 
a trend existed for the others factors tested, 
none of them reached the level of statistical 
significance. 
DISCUSSION 
This cohort study shows that in Rwanda, 
mortality among children born to seroposi- 
tive mothers is high in the first 2 years of 
life, occurs early, and is principally due to 
diarrheal diseases and pulmonary infections. 
This mortality rate (1 9 percent for the first 
2 years of life), although lower than in other 
African studies (5, 7) is two- to threefold 
higher than among European children born 
to HIV-1 seropositive mothers (IO, 11). 
Diarrheal diseases and pulmonary infec- 
tions, the principal causes of death in chil- 
dren under age 5 years in the developing 
world (27, 28), are also the major causes of 
death in children born to seropositive moth- 
ers in this study. Therefore, the increased 
mortality in children born to seropositive 
mothers in Africa may, at least in part, be 
explained by greater exposure to enteric and 
respiratory pathogens. As seropositive and 
seronegative mothers in our sample were 
similar in terms of socioeconomic status and 
parity (19), we assume that the high rate of 
mortality in children born to HIV-1 sero- 
positive mothers is related with maternal 
HIV-1 infection. Among the children born 
to seronegative mothers, the mortality dur- 
ing the first 2 years is lower than expected 
in Rwandan children. This finding is prob- 
ably related to the regular follow-up and 
improved medical care provided to the chil- 
dren in our cohort. This is consistent with 
mortality experience documented in the 
other African studies (5, 7) of mother-to- 
child transmission of HIV- I.  
In this study, HIV-1 infected and unin- 
fected children were immunized with a high- 
dose Edmonston-Zagreb measles vaccine at 
6 months of age (20). A recent study from 
Senegal strongly suggests that child mortality 
is higher among those receiving high-dose 
measles vaccines than among those given 
the standard vaccine (29). A follow-up of 
the survival experience of the cohort is there- 
fore planned until 48 months of age to con- 
firm the low mortality figures presented in 
this report for the first 2 years of follow-up. 
Half of the children born to HIV-1 sero- 
positive women in our cohort have lost their 
maternally acquired antibodies at 9 months 
of age. This is consistent with other studies 
either in Africa (5) or in the United States 
(13). We can consider that in our sample, 
the loss of maternal antibodies is Virtually 
achieved at 12 months of age. 
In this prospective cohort study, the trans- 
mission rate of HIV-1 from mother to child 
was 25.7 percent with method I and 24.7 
percent with method 2 (medium estimate) 
with 95 percent confidence intervals yielding 
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a range of possible values of 18 percent to 
3 1 percent. These figures are in the low range 
of other perinatal studies carried out in 
Africa (Kinshasa, Zaire, 39 percent (5); 
Lusaka, Zambia, 39 percent (6); Brazzaville, 
Congo, 52 percent (7)). By contrast, most 
perinatal studies from industrialized coun- 
tries have documented lower transmission 
rates. The largest published study, the 
European Collaborative Study, has analyzed 
a cohort of 372 children of seropositive 
mothers born at least 18 months before the 
analysis from 10 different centers in Europe; 
the mother-to-child transmission rate was 
14.4 percent in this group of children (16). 
In the French Collaborative Study, the trans- 
mission rate of 528 children with suficient 
follow-up is currently estimated at 19 per- 
cent ( I  8). It should, however, be emphasized 
that comparisons between studies are made 
dificult because the methods of calculating 
the mother-to-child transmission rates are 
different from one study to another (18). We 
used two different methods to estimate the 
rate of transmission. The case-by-case eval- 
uation (method 2) should be considered as 
a reference method, is applicable in any 
setting, and can be used for the study of the 
determinants of transmission. However, this 
method yields a number of children with 
indeterminate status for HIV- 1 infection. In 
our study, 15 percent of the children born 
to HIV-1 seropositive mothers remained 
with an indeterminate HIV- 1 infection sta- 
tus. Although this can be considered as ac- 
ceptable, the consequence is a wide range of 
values of the transmission rate with lower, 
medium and upper estimates. The other 
method (method 1) is an attempt to solve 
the problem of the case-by-case classifica- 
tion. It requires a comparison group. The 
use of method 1 has been challenged on the 
grounds that uninfected infants born to Sero- 
positive mothers might be at higher risk of 
mortality independently of HIV- 1 infection 
and that, consequently, the method would 
overestimate the transmission rate (3). It is 
worth noting that, in our study, the two 
methods gave comparable estimates of the 
rate of transmission. With both methods, we 
report estimates of the transmission rate 
with possible ranges of values and confi- 
dence intervals. We believe that this ap- 
proach should be preferred and that other 
investigators may experience the same vari- 
ability around their point estimate if such 
computations were done. 
It has been suggested that bias toward a 
higher rate of transmission was introduced 
in some African studies with a high rate of 
loss to follow-up (3). However, in the present 
study, the loss to follow-up rate did not 
exceed 4 percent when we consider the 
period during which children lost to follow- 
up remain with an indeterminate status for 
HIV- 1 infection. If one admits that bias was 
limited in this cohort study, one could dis- 
cuss the reasons for the discrepancy in rates 
of transmission between this study and 
other African studies on one hand, and the 
European Collaborative and French studies 
on the other hand. 
It is plausible that African HIV- 1-infected 
mothers have on the average worse health 
status than seropositive mothers from indus- 
trialized countries and might therefore trans- 
mit HIV- 1 more efficiently to their offspring. 
However, in all but one study (5) among the 
perinatal studies from Africa, the vast ma- 
jority of women were asymptomatic at the 
time of enrollment (6-8). Although none of 
the seropositive mothers in our study had 
AIDS at enrollment (19), the majority had 
evidence of cell-mediated immunologic im- 
pairment. Indeed, 72 percent of the seropos- 
itive mothers had a CD4/CD8 ratio lower 
than 1 when tested 15 days after delivery; a 
third of those had a CD4/CD8 ratio lower 
than 0.5 (19). It is therefore conceivable that 
immunologic deficiency is more prevalent 
among HIV- 1 infected women in Africa due 
to their nutritional status or the infectious 
environment. 
The longer time interval since contami- 
nation in populations where HIV- 1 has been 
circulating for several years is another pos- 
sible explanation for the high frequency of 
low CD4/CD8 ratios encountered in our 
sample. The role of a reversed maternal 
CD4/CD8 ratio or a decreased CD4 cell 
count as risk factors of mother-to-child 
transmission has recently been demon- 
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strated in the European Collaborative Study 
(16). In our study, mothers with a CD4/ 
CD8 ratio lower than 0.5 transmitted HIV- 
1 infection more frequently to their infants, 
as shown in both univariate and multivariate 
analyses. 
Other maternal factors, such as clinical 
status, mode of delivery, or sexually trans- 
mitted diseases were not associated with in- 
creased risk of transmission. It is possible 
that as few women in our sample were symp- 
tomatic at delivery, a difference was impos- 
sible to document for this factor. The same 
limitation has been encountered for mode 
of delivery, with few cesarean sections per- 
formed in the study sample. A history of 
adverse pregnancy outcome was related with 
pediatric HIV- 1 infection in the univariate 
analysis but not in the multivariate analysis. 
This variable could be an indicator of length 
of maternal HIV-1 infection and not a de- 
terminant of transmission. Finally, no other 
maternal factor than the CD4/CD8 ratio 
remained important in the multivariate 
model, reflecting their limited contribution 
to mother-to-child transmission of HIV-1 in 
contrast to the European Collaborative 
Study findings (16). We decided not to in- 
clude in the analysis low birth weight and 
prematurity as possible determinants of 
transmission. Indeed, the .causal pathway 
between these events and pkdic$ric HIV-1 
infection is speculative. 
The role of breast feeding in mother-to- 
child postnatal HIV- 1 transmission is now 
well established (4, 16, 30-37). Breast feed- 
ing was universal and prolonged in our pop- 
ulation as well as in the other African studies 
(5-7), whereas only 5 percent of European 
women enrolled in such studies breast-fed, 
usually for a short period (1 1 , 16). In our 
study, HIV-1 infected cells were detected by 
the polymerase chain reaction test in 47 
percent of breast milk samples of seroposi- 
tive mothers tested 15 days after delivery 
(38). Quantitating the excess risk attribut- 
able to breast feeding among children whose 
mothers are seropositive for HIV-1 at the 
time of delivery is extremely difficult for 
numerous methodological and ethical rea- 
sons (39) and cannot be done in the present 
study. 
In conclusion, our findings are consistent 
with other studies from Africa and present 
evidence for a higher mother-to-child trans- 
mission rate of HIV-1 in children born in 
Africa than in industrialized countries. This 
difference in rate might result from different 
clinical/immunologic characteristics of the 
mothers and/or from postnatal transmission 
of HIV-1 through breast milk. Studies are 
needed to better define the clinical and im- 
munologic characteristics of mothers en- 
rolled in perinatal studies and to evaluate 
the additional risk of breast feeding among 
infants of seropositive women. 
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